Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Dib

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
JCO Precision Oncology|February 9, 2022
Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational StudySteven F Powell, Elie G Dib, Jonathan S Bleeker, et al.
JCO Precision Oncology|April 30, 2026
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry StudyErin F Cobain, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2024
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With <i>ERBB2/3</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyTimothy L Cannon, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2026
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005Kristin A Higgins, Chen Hu, Helen J Ross, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
JCO Precision Oncology|February 9, 2022
Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational StudySteven F Powell, Elie G Dib, Jonathan S Bleeker, et al.
JCO Precision Oncology|April 30, 2026
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry StudyErin F Cobain, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2024
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With <i>ERBB2/3</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyTimothy L Cannon, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2026
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005Kristin A Higgins, Chen Hu, Helen J Ross, et al.
Pageof 6